Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT04221542)
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (57 Sites)
Showing the first 25 of 57 sites.
- City of Hope National Medical Center — Duarte, California
- Providence Saint Jude Medical Center — Fullerton, California
- University of California San Francisco — San Francisco, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Yale New Haven Hospital — New Haven, Connecticut
- Emory University — Atlanta, Georgia
- Indiana University — Indianapolis, Indiana
- MidAmerica Cancer Care — Merriam, Kansas
- Tulane Medical Center — New Orleans, Louisiana
- Washington University — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
- Oncology Hematology Care Incorporated — Cincinnati, Ohio
- Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Prisma Health Upstate — Greenville, South Carolina
- Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
- United States Oncology Regulatory Affairs Corporate Office — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- US Oncology Research Investigational Products Center — Irving, Texas
- Intermountain Medical Center — Murray, Utah
- Virginia Cancer Specialists PC — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.